Could anti-CD20 therapy jeopardise the efficacy of a SARS-CoV-2 vaccine?

被引：53

作者：

Houot, Roch ^{[1
,2
]}

Levy, Ronald ^{[3
]}

Cartron, Guillaume ^{[4
]}

Armand, Philippe ^{[2
]}

机构：

[1] Univ Rennes, INSERM U1236, CHU Rennes, Dept Hematol, Rennes, France

[2] Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02115 USA

[3] Stanford Univ, Sch Med, Dept Med Oncol, Stanford, CA USA

[4] Univ Montpellier, Inst Genet Mol Montpellier, CHU Montpellier,Univ Hospitality, Dept Hematol,CNRS UMR 5535, Montpellier, France

来源：

EUROPEAN JOURNAL OF CANCER | 2020年 / 136卷

关键词：

COVID-19; SARS-CoV-2; Vaccine; Anti-CD20; antibody; Rituximab; INFLUENZA VACCINATION; LYMPHOMA PATIENTS; RITUXIMAB; RESPONSES;

D O I：

10.1016/j.ejca.2020.06.017

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

A vaccine against SARS-CoV-2 might represent the most promising approach to halt durably the current COVID-19 pandemic. We believe that anti-CD20 therapy may jeopardise the efficacy of such a vaccine. This is regrettable because patients receiving anti-CD20 therapy (i.e. those with haematologic malignancies or autoimmune disorders) are particularly at risk of severe COVID-19 and, as such, are the most in need of a vaccine. Here, we review the reasons why anti-CD20 therapy may abrogate or diminish the efficacy of a vaccine against SARS-CoV-2 and we draw physicians' attention towards this potential risk so that it can be considered when evaluating the risk/benefit ratio of anti-CD20 therapy during the current pandemic. (C) 2020 Elsevier Ltd. All rights reserved.

引用

页码：4 / 6

页数：3

共 19 条

[1] Impaired Response to Influenza Vaccine Associated with Persistent Memory B Cell Depletion in Non-Hodgkin's Lymphoma Patients Treated with Rituximab-Containing Regimens [J].

Bedognetti, Davide ;

Zoppoli, Gabriele ;

Massucco, Carlotta ;

Zanardi, Elisa ;

Zupo, Simonetta ;

Bruzzone, Andrea ;

Sertoli, Mario Roberto ;

Balleari, Enrico ;

Racchi, Omar ;

Messina, Marco ;

Caltabiano, Graziano ;

Icardi, Giancarlo ;

Durando, Paolo ;

Marincola, Francesco M. ;

Boccardo, Francesco ;

Ferrarini, Manlio ;

Ansaldi, Filippo ;

De Maria, Andrea .

JOURNAL OF IMMUNOLOGY, 2011, 186 (10) :6044-6055

[2] Immunization Responses in Rheumatoid Arthritis Patients Treated With Rituximab Results From a Controlled Clinical Trial [J].

Bingham, Clifton O., III ;

Looney, R. John ;

Deodhar, Atul ;

Halsey, Neal ;

Greenwald, Maria ;

Codding, Christine ;

Trzaskoma, Benjamin ;

Martin, Flavius ;

Agarwal, Sunil ;

Kelman, Ariella .

ARTHRITIS AND RHEUMATISM, 2010, 62 (01) :64-74

[3]

Chandrashekar A, 2020, SCIENCE, DOI [10.1126/SCIENCE.ABC4776, DOI 10.1126/SCIENCE.ABC4776(80-)]

[4] A strategic approach to COVID-19 vaccine R&D [J].

Corey, Lawrence ;

Mascola, John R. ;

Fauci, Anthony S. ;

Collins, Francis S. .

SCIENCE, 2020, 368 (6494) :948-950

[5] Vaccines for the prevention against the threat of MERS-CoV [J].

Du, Lanying ;

Tai, Wanbo ;

Zhou, Yusen ;

Jiang, Shibo .

EXPERT REVIEW OF VACCINES, 2016, 15 (09) :1123-1134

[6] Rituximab-Treated Patients Have a Poor Response to Influenza Vaccination [J].

Eisenberg, Robert A. ;

Jawad, Abbas F. ;

Boyer, Jean ;

Maurer, Kelly ;

McDonald, Kenyetta ;

Prak, Eline T. Luning ;

Sullivan, Kathleen E. .

JOURNAL OF CLINICAL IMMUNOLOGY, 2013, 33 (02) :388-396

[7] Reduced antibody formation after influenza vaccination in patients with neuromyelitis optica spectrum disorder treated with rituximab [J].

Kim, W. ;

Kim, S. -H. ;

Huh, S. -Y. ;

Kong, S. -Y. ;

Choi, Y. J. ;

Cheong, H. J. ;

Kim, H. J. .

EUROPEAN JOURNAL OF NEUROLOGY, 2013, 20 (06) :975-980

[8] Effect of Convalescent Plasma Therapy on Time to Clinical Improvement in Patients With Severe and Life-threatening COVID-19 A Randomized Clinical Trial [J].

Li, Ling ;

Zhang, Wei ;

Hu, Yu ;

Tong, Xunliang ;

Zheng, Shangen ;

Yang, Juntao ;

Kong, Yujie ;

Ren, Lili ;

Wei, Qing ;

Mei, Heng ;

Hu, Caiying ;

Tao, Cuihua ;

Yang, Ru ;

Wang, Jue ;

Yu, Yongpei ;

Guo, Yong ;

Wu, Xiaoxiong ;

Xu, Zhihua ;

Zeng, Li ;

Xiong, Nian ;

Chen, Lifeng ;

Wang, Juan ;

Man, Ning ;

Liu, Yu ;

Xu, Haixia ;

Deng, E. ;

Zhang, Xuejun ;

Li, Chenyue ;

Wang, Conghui ;

Su, Shisheng ;

Zhang, Linqi ;

Wang, Jianwei ;

Wu, Yanyun ;

Liu, Zhong .

JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2020, 324 (05) :460-470

[9] Rituximab chimeric Anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma:: Half of patients respond to a four-dose treatment program [J].

McLaughlin, P ;

Grillo-López, AJ ;

Link, BK ;

Levy, R ;

Czuczman, MS ;

Williams, ME ;

Heyman, MR ;

Bence-Bruckler, I ;

White, CA ;

Cabanillas, F ;

Jain, V ;

Ho, AD ;

Lister, J ;

Wey, K ;

Shen, D ;

Dallaire, BK .

JOURNAL OF CLINICAL ONCOLOGY, 1998, 16 (08) :2825-2833

[10] Case Fatality Rate of Cancer Patients with COVID-19 in a New York Hospital System [J].

Mehta, Vikas ;

Goel, Sanjay ;

Kabarriti, Rafi ;

Cole, Daniel ;

Goldfinger, Mendel ;

Acuna-Villaorduna, Ana ;

Pradhan, Kith ;

Thota, Raja ;

Reissman, Stan ;

Sparano, Joseph A. ;

Gartrell, Benjamin A. ;

Smith, Richard, V ;

Ohri, Nitin ;

Garg, Madhur ;

Racine, Andrew D. ;

Kalnicki, Shalom ;

Perez-Soler, Roman ;

Halmos, Balazs ;

Verma, Amit .

CANCER DISCOVERY, 2020, 10 (07) :935-941

← 1 2 →